McGrath MF, Ogawa T, de Bold AJ. Ras dexamethasone-induced protein 1 is a modulator of hormone secretion in the volume overloaded heart. Am J Physiol Heart Circ Physiol 302: H1826 -H1837, 2012. First published March 12, 2012 ; doi:10.1152/ajpheart.01085.2011.-Because of the crucial role of the endocrine heart in maintaining homeostasis, considerable effort has been focused on the elucidation of the mechanistic underlying gene expression and secretion of the cardiac hormones atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP). However, much remains to be determined regarding specific molecular events involved in cardiocyte secretory function. In this work, we identified genes involved in the transcriptional response of the endocrine heart to volume overload (VO) and signaling pathways involved in its regulation. To this end, the cardiac atrial and ventricular transcriptomes were analyzed in the heart of rats subjected to experimentally induced aorto-caval shunt VO. Pathway analysis revealed unique gene expression profiles in the VO atria for G-protein signaling, notably a significant downregulation of Ras dexamethasone-induced protein 1 (RASD1). In vitro, knockdown of RASD1 in the atrial-derived HL-1 cells, significantly increased ANF secretion. Concurrent knockdown of RASD1 and its effectors G␣ o1 or G␤1␥2 abrogated the endocrine response, demonstrating a previously unknown negative modulator role for RASD1. RASD1 thus emerges as a tonic inhibitor of ANF secretion and illustrates for the first time the concept of inhibitory protein regulators of ANF release. The novel molecular function identified herein for RASD1 is of considerable importance given its therapeutic implications for cardiovascular disease.
gene expression array; natriuretic peptides; atrial natriuretic factor; heterotrimeric G proteins; ribonucleic acid interference CARDIOVASCULAR DISEASE (CVD) is responsible for more deaths globally than any other disease, with an estimated 17.1 million deaths in 2004 (World Health Organization: http://www.who.int/ mediacentre/factsheets/fs317/en/index.html). CVD encompasses a wide range of cardiac and circulatory pathologies, including heart failure. Pathological cardiac hypertrophy, resulting from prolonged mechanical and/or neurohumoral stimuli, is the single most powerful predictor of the clinical course of heart failure, and it is an important risk factor for cardiovascular mortality in humans (1) . Cardiac hypertrophy is associated with the chronic increase in circulating levels of both vasoconstrictive and vasodilatory hormones (26) , including those associated with the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, as well as the cardiac natriuretic peptides (NPs), atrial natriuretic factor (ANF), and brain natriuretic peptide (BNP), respectively. The NPs oppose the vasoconstrictive hormonal systems and their cardiovascular growth-promoting effects. The latter effect is important in the context of cardiovascular remodeling (34) .
Considerable effort has been focused on the elucidation of the mechanistic underlying ANF and BNP gene expression and secretion by the atrial cardiocytes but much remains to be determined regarding specific signaling events involved in the cardiocyte secretory function. G-protein participation in stimulated NP secretion from the atria involves G i/o -or G q -class proteins (2) . G i/o signaling mediates the increase in circulating NP following mechanical stretch of the atria (stretch-secretion coupling; Ref. 21 ) as may be observed by increasing intraatrial distension resulting from a normal (e.g., head-out water immersion) or pathological increase in venous return (e.g., congestive heart failure; Refs. 25, 28) . Increased atrial distension by volume overload (VO) is also accompanied by an increased expression and secretion of both NPs.
Other than the aforementioned involvement of G i/o in the activation of the endocrine heart brought about by atrial muscle stretch, little is known about the participation of other molecules in this important mechanism. In the work reported here, we carried out a time-course investigation in vivo to define the overall gene expression profile associated with stretch activation of the endocrine heart following an increase in venous return to the heart obtained by aorto-caval shunt (14, 15, 35 ). We found that the level of expression of the regulator of G-protein signaling Ras dexamethasone-induced protein 1 (RASD1) was particularly affected by VO. Since this regulator is known to be involved in G i/o signaling, which, in turn, is involved in stretch-secretion coupling, we further defined the effect of varying its level of expression on ANF secretion in vitro by RNA interference (RNAi) knockdown using the atrial cardiocyte-derived HL-1 cell line. The results obtained support the view that RASD1 plays a significant role in the regulation of cardiac hormone secretion.
MATERIALS AND METHODS

Surgical Procedure
The aorto-caval shunt was produced in rats by a method previously described (10) . A laparotomy was performed in Sprague-Dawley rats (225-275 g; Charles River Laboratories, Wilmington, MA) while the animals were under isoflurane anesthesia. The abdominal aorta and vena cava were clamped, and an 18-gauge needle was used to puncture the abdominal aorta below the left renal artery. The needle was pushed within the vessel and redirected towards the adjacent vena cava until puncturing of the vena cava. After removal of the needle, cyanoacrylate glue (Krazy glue) was applied to the puncture to seal the wound. The sham-operated rats underwent the same surgical procedure with the exclusion of the vessel puncture. The rats were killed by decapitation 1, 2, 7, and 28 days postsurgery. The tissues were wrapped in aluminum foil and snap frozen in liquid nitrogen and stored at Ϫ80°C. Each shunt (VO) and sham groups was comprised of six rats. The experimental protocol was carried out according to the Canadian Council on Animal Care's Guide to the Care and Use of Experimental Animals following approval by the University of Ottawa Animal Care Committee.
Plasma Samples
Trunk blood samples were collected in chilled Vacutainer tubes containing EDTA (VWR International, Mississauga, ON, Canada). Plasma was immediately separated by centrifugation at 2,000 g for 20 min at 4°C and then stored in cryovials at Ϫ80°C until assayed. Upon thawing, plasma samples were acidified by addition 100 l 1.0 N HCl/ml plasma and extracted with Sep-Pak C 18 cartridges (Millipore-Waters, Milford, MA). Radioimmunoassay was performed using the double antibody technique as previously described by Sarda et al. (30) .
Total RNA Extraction
Total RNA was extracted from 1, 2, 7, and 28 day postsurgery left and right atria appendages as well as left ventricular free wall and right ventricle of sham and aorto-caval shunt operated rats using Qiagen RNeasy Mini columns (Mississauga, ON, Canada), following the manufacturer's instructions. For GeneChip hybridization, RNA extracted from the 28-day time point was pooled to create three biological replicate per group. Total RNA was extracted from HL-1 cells using 1 ml of Trizol (Invitrogen, Carlsbad, CA) per tissue culture well, following the manufacturer's instructions. The quality of the extracted total RNA was assessed by the Agilent 2100 Bioanalyzer, using the Agilent RNA 6000 Nano kit (Agilent Technologies, Palo Alto, CA).
Microarray Hybridization and Analysis
Ten micrograms of total RNA were used to generate the first-strand cDNA using the one cycle target labeling protocol. The biotin-labeled cRNA was prepared according to the manufacturer's protocol and hybridized to the GeneChip Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, CA). Detailed description of the hybridization protocol is available at https://genomequebec.mcgill.ca/nanuqAdministration/ nanuq-administration/protocols.go. Three biological replicates per tissue type were generated for the sham and VO operated animals. These steps were carried out by the Genome Québec Innovation Centre (Montreal, QC, Canada).
The files containing cell intensities (.CEL) were visually inspected with the dChip (www.dchip.org) and Flexarray (http://genomequebec-.mcgill.ca/FlexArray/) softwares as a quality control measure to identify local image artifact before normalization. The expression level summary files were computed by robust multiple-array averaging (RMA), which is implemented in Bioconductor (www.bioconductor.org). For multiple group comparisons, differential expression of genes was considered to be significant based on a two-way ANOVA with a P Ͻ 0.001 and a false discovery rate (FDR) adjusted P Ͻ 0.045 [factor 1: tissue, factor 2: condition (VO or sham)]. For the two group comparisons, differential expression of genes was considered to be significant based significance analysis of microarrays (SAM; wwwstat.stanford.edu/ϳtibs/SAM) with a FDR of 0.1%. Genes were considered biologically differentially expressed based on an up-or downregulation of expression levels by Ն1.5-fold. Sample hierarchical clustering was performed with TIGR MeV software (http:// www.tm4.org/) using the Pearson uncentered correlation with complete linkage. All biological replicates clustered together (not shown). Pathway analysis, which identifies biologically relevant networks that exist among differentially expressed genes, was done by GenMAPP software (www.genmapp.org). Functional annotation clustering and gene functional classification was carried out using Database for Annotation, Visualization, and Integrated Discovery (DAVID; http:// david.abcc.ncifcrf.gov/). Statistically overrepresented Gene Ontology (GO) terms were assessed with the GOstat program (www.gostat.wehi.edu.au/). The microarray data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) and complies with MIAME standards (accession no. GSE12758).
Real-Time RT-PCR
Real-time RT-PCR was used to validate expression profiles of selected genes. One microgram of total RNA was used for reverse transcription, using the transcriptor first-strand cDNA synthesis kit (Roche Diagnostics, Laval, QC, Canada). Quantitative PCR was performed using the LightCycler 480 SYBR green 1 Master, according to the manufacturer's protocol (Roche Diagnostics). The analysis was performed using the Roche LightCycler 480 relative quantification software. Primer nucleotide sequences were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/input.htm) or designed by Integrated DNA Technologies (Table 1) . Standard curves were constructed in triplicate for each primer pair. Glucose-6-phosphate dehydrogenase was used as the reference gene. Ribosomal protein L23 (RPL23) was used as the reference gene in the knockdown experiments. Concentration ratios were subjected to calibrator normalization and efficiency correction.
Cell Line and Culture
The immortalized cell line HL-1 derived from AT-1 mouse atrial cardiocytes, was a generous gift from Dr. W. C. Claycomb (Louisiana State University, New Orleans, LA; Ref. 9). In a 24-well plate, HL-1 cells were seeded at an initial density of 50,000 cells/well. HL-1 cells were cultured at 37°C under 5% CO 2 on precoated gelatin/fibronectin wells in antibiotic-free Claycomb medium supplemented with 10% FBS, 0.1 mM norepinephrine, and 2 mM L-glutamine (37) .
Immunofluorescence
HL-1 cells were culture on precoated gelatin/fibronectin microscope slides for 48 h and fixed in 2% PFA for 30 min at room temperature. The fixed cells were then blocked with 5% normal goat serum in PBS for 60 min followed by a single wash in PBS. The cells were then incubated with primary antibody in 2% normal goat serum and 2% BSA in PBS overnight at 4°C and then incubated for 60 min with biotinylated goat anti-rabbit IgG. RASD1 primary antibody (AB15794; Millipore) dilution was 1:1,000; G␣ o primary antibody dilution was 1:200 (551; MBL, Japan). Slides were then washed in PBS, incubated with fluorescein avidin D for 30 min, washed in PBS and distilled water and mounted using Vectashield mounting media with DAPI (Vectorlabs), and examined with a Leica fluorescence confocal microscope. For double immunofluorescence labeling, sections were incubated overnight with primary antibody against the first antigen, RASD1, as above. Following avidin D and biotin blocking treatment (avidin/biotin blocking kit, SP-2,001; Vector Laboratories), sections were incubated in citric phosphate buffer, pH 2.2 for 1 h. Sections were then incubated with second primary antibody, against G␣ o, as described above.
RNAi-Mediated Silencing of RASD1 in HL-1 Cells
The 27-mer double-stranded RNA (dsRNA) duplexes targeting RASD1, G␣o, G␤1, and G␥2, as well as the controls (scrambled universal negative control, HPRT-S1-DS-positive control, and TYE 563-labeled transfection controls) were designed and synthesized by Integrated DNA Technologies (Integrated DNA Technologies, Coralville, IA), as part of the TriFECTa kit. ANF-targeted siRNA oligonuceotides were designed and synthesized by Dharmacon (ThermoScientific, Lafayette, CO).
Twenty-four hours after plating HL-1 cells, 10 nM of dsRNA (Integrated DNA Technologies) or 100 nM siRNA (Dharmacon; Thermo-Scientific) were transfected into HL-1 cells using Dharma-FECT1 (Thermo-Scientific) transfection reagent, according to the manufacturer's instructions. Media were collected and replaced with fresh antibiotic-free Claycomb media every 24 h. HL-1 cells were harvested at 48 and 72 h posttransfection.
Pharmacological Stimulation
The mastoparan-7 (7.5 M; Sigma-Aldrich) effect on ANF secretion was determined in HL-1 cells. Media were collected at various time points, and ANF secretion levels were determined by radioimmunoassay.
ANF Radioimmunoassay
ANF levels were determined in 100-l aliquot media samples using the double antibody RIA technique, as described by Sarda et al. (30) . Antisera against ANF 99 -126 (Peninsula Laboratories) were used.
Protein Extraction
HL-1 cells were washed once with ice-cold PBS and scraped with ice-cold RIPA buffer (150 mM NaCl, 50 mM Tris·HCl pH 7.4, 1 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 5 g/ml protease inhibitor cocktail, and 1 mM PMSF). Lysate was incubated for 1 h at 4°C with orbital shaker and stored at Ϫ80°C overnight. Samples were then centrifuged at 10,000 rpm for 10 min at 4°C. The pellet was discarded, and the protein concentration of the supernatant was determined using the bicinchoninic acid protein assay kit (Pierce, Thermo-Scientific).
Differential centrifugation was used to isolate the microsomal fraction from homogenized heart tissue. The left and right atria and the left ventricular free wall were obtained from male SpragueDawley rats (225-275 g; Charles River Laboratories, Wilmington, MA), killed by decapitation. Atrial and ventricular tissues were, respectively, homogenized with a polytron in ice-cold buffer (50 mM Tri·HCl pH 7.4, 1 mM EDTA pH 8.0, 100 mM NaCl, 10 mM DTT, 1 mM PMSF, and proteinase inhibitor cocktail). The samples were further processed with a glass homogenizer. The final homogenate was centrifuged at 1,900 g max for 10 min at 4°C with JA-20 rotor (J-21 series centrifuge). The postnuclear supernatant was collected. The pellet was rehomogenized and centrifuged at 1,900 g max for 10 min at 4°C. The supernatants from both centrifugations were pooled. The pooled supernatants were centrifuged at 1,900 g max for 10 min at 4°C. The supernatant was collected and centrifuged at 32,000 gmax for 10 min at 4°C. The supernatant was aliquoted into polycarbonate tubes and ultracentrifuged at 144,880 gav for 90 min at 4°C with 50.2 Ti rotor ultracentrifuge. The membrane protein pellet was homogenized with a glass Potter Elvehjem and solubilized overnight at 4°C in RIPA buffer (150 mM NaCl, 50 mM Tris, 1 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM PMSF, and 5 ug/ml proteinase inhibitor cocktail). Protein concentration was determined by bicinchoninic acid protein assay kit (Pierce, Thermo-Scientific).
Western Blot Analysis
Before electrophoresis, protein samples taken up in 3ϫ sample buffer and DTT were heated for 4 min at 95°C. Samples were loaded on a 10 -20% precast linear gradient polyacrylamide Tris·HCl Ready Gel (Bio-Rad, Mississauga, ON, Canada), run at room temperature for 45 min, at 200 V, and transferred onto a PVDF membrane either at 100 V for 1 h or overnight at 4°C at 67 V. Membranes were blocked [blocking buffer: Tris-buffered saline Tween-20 (TBST), 5% wt/vol nonfat milk] for 1 h at room temperature. Blots were washed three times with TBST for 5 min and incubated overnight at 4°C in primary antibody dilution buffer (TBST, 5% wt/vol nonfat milk). Primary antibody dilutions were as follows: G␣ o 1:1,000 (551; MBL), RASD1 1:1,000 (AB15794; Millipore), ␣-tubulin 1:400 (sc-8035; Santa Cruz Biotechnology, Santa Cruz, CA), and pro-ANF 1:1,000 [rabbit 5, bleed 8 (R5B8)]. Membranes were washed three times with TBST for 5 min. The immune complex was detected by using secondary antibodies conjugated to horseradish peroxidase enzyme (goat antirabbit, sc-2004; Santa Cruz Biotechnology), goat anti-mouse (sc-2005; Santa Cruz Biotechnology), and anti-biotin (Cell Signaling Technology, Danvers, MA) followed by enhanced chemiluminescence, Supersignal west Femto (Pierce, Fisher Scientific). Images were taken with the FluroChem Imaging System (Alpha Innotech). The biotinylated protein ladder (77275; Cell Signaling Technology) and kaleidoscope protein ladder (161-0375; Bio-Rad Life Science) were also loaded on the gels. 
Statistical Analysis
Values are means Ϯ SD. To determine pairwise statistical differences, Student's t-tests were performed. P Ͻ 0.05 was considered significant.
RESULTS
Development of Cardiac Hypertrophy
Body weight did not differ between the VO and shamoperated rats over the 4-wk period (Fig. 1A) . The progression of cardiac hypertrophy of the VO animals is shown in Fig. 1 , B-E. All four cardiac chambers exhibited significant hypertrophy in VO rats by 28 days postsurgery.
Time Course Measurements of Plasma ANF and BNP Levels and Gene Expression
VO significantly increased plasma ANF and BNP levels by more than twofold at days 2, 7, and 28, compared with the sham-operated rats (Fig. 2) . Across all time points, ANF plasma levels were on average 10-fold higher than BNP plasma levels. In sham-operated rats, ANF and BNP plasma levels did not change throughout the experimental period.
Cardiac ANF and BNP gene expression levels significantly increased as hypertrophy progressed (Fig. 3) . Both ANF and BNP specific transcripts were significantly higher in all cardiac chambers of the VO rats on days 7 and 28. As early as day 2, the right ventricles exhibited the first signs of increased ANF mRNA levels, while an increase in BNP mRNA was observed in the left atria.
Gene Expression Analysis
Differentially expressed genes in VO atria. Gene expression analysis, at the 28-day time point, identified 700 probe sets that exhibited a significant experimental condition effect, as evidenced by a two-way ANOVA analysis (P value Ͻ0.001; FDR 0.045) between hemodynamically overloaded atria and their sham counterpart (Supplemental Table 1 ; Supplemental Material for this article is available online at the Am J Physiol Heart Circ Physiol website). Four-hundred and eight probe sets were induced in the VO atrial samples whereas 292 probe sets exhibited a downregulation in the same samples. Hallmark cardiac hypertrophic genes that were induced in the VO atria included ANF, BNP, ␣-actin-1, and ␤-myosin heavy chain. ␣-Actin-1 and ␤-myosin heavy chain were upregulated in the VO animals by 3.01-and 3.79-fold, respectively.
Ranking in the top 25 significantly differentially expressed probe sets (P value Ͻ1.3 ϫ 10 Ϫ7 ; FDR Ͻ0.0032) was the insulin-like growth factor binding protein 3 (Igfbp3), which is downregulated in VO conditions. Other significantly repressed genes included fibrinogen gamma polypeptide, sodium/potassium/calcium exchanger (Slc24a3), Hsdl2, as well as the modulator of G i/o protein signaling RASD1. VO significantly induced skeletal ␣-actin 1, ankyrin repeat domain 1 (Ankrd1), SCHIP-1, intersectin 2, ADP-ribosyltransferase 3, Bnip3, Wisp2, Ppp1r3c, and Psme4. Ten unknown genes were listed within these top 25 probes sets.
Signal transduction transcripts that were differentially expressed between the sham and VO animals included the Gprotein-coupled receptors (GPCR) signaling pathway proteins Agtrl1, Cxcr4, Fzd2, Eltd1, Gprk6, Igf2, RGS3, and CD97, as well as Smo, Edg2, RhoGEF17, and RASD1, upregulated and downregulated, respectively. Growth factors that were differentially expressed included BMP4 and 6, IGF2, FGF9 and 12, TGF␤ 2 , and VEGFA. Upregulated transcripts involved in cell surface mechanosensing in addition to Ankrd1 included osteoglycin and ␣ 5 -integrin. The calcium binding proteins S100A4, S100A6, and S100A10 were all upregulated in the VO atria. The S100A10 binding partner, annexin-A2, was also upregulated by 1.38-fold. Other members of the soluble Nethylmaleimide-sensitive factor attachment protein receptors (SNAREs) complex that were upregulated included vesicleassociated membrane proteins 1 and 3 and syntaxin 11.
Atria vs. ventricular differential gene expression in VO. Atrial and ventricular gene expression differences from the VO animals were determined based on a SAM statistical analysis with FDR for multiple testing correction. A total of 1,975 genes were found significantly differentially expressed between the two groups, at a 1.5-fold cut-off (Supplemental Table 2 ). One-thousand one-hundred forty-seven genes were more abundant in the atria, while 828 genes were more abundant in the ventricles.
Statistically overrepresented Gene Ontology (GO) terms (P Ͻ 0.001) were determined using GOstat software. Nine GO terms were found overrepresented in the VO atria, including endoplasmic reticulum, membrane part, cellular secretion, secretory pathway, and protein transport. Atrial abundant transcripts that had GO annotations related to secretion are listed in Table 2 . Figure 4 depicts a Venn diagram illustrating the number of differentially expressed genes obtained following a two-way ANOVA analysis (P value Ͻ0.001; FDR 0.045) for each factor [i.e., tissue (atria vs. ventricles) or condition (sham vs. VO)] and their interaction, i.e., genes that are differentially expressed due to the experimental condition as well as their tissue origin. Several heterotrimeric G-protein subunits were differentially expressed between the VO atria and ventricles, including ventricular G␥ 5 (1.3-fold), atrial G␣ o1 (5.06-fold), G␤ 5 (1.58-fold), and G␥ 2 (2.78-fold). A probe set with high similarity to human RGS6 was 2.58-fold more abundant in the VO atria compared with the ventricles. Fifty-two transcripts were found to exhibit an interaction effect between the two factors: tissue and condition. These included transcripts involved in the regulation of G-protein signaling RASD1, RGS3, and RGS4. As previously identified above, RASD1 was significantly downregulated in the VO atria compared with sham by 3.85-fold while no significant change was observed in the ventricles. Furthermore, RASD1 was significantly more abundant in the sham atria compared with the sham ventricles by 5.59-fold. The differential expression of RASD1 in atrial and ventricular tissues under both sham and VO shunt conditions can be readily visualized by a heat map (Fig. 5) .
Validation. Gene expression profile analysis identified numerous candidate genes involved in the regulation of the endocrine function of the heart. A subset of these genes that is known to be either involved in hormone secretion (Snca1 and ICA1), signaling (Wips2, Gja4, RASD1, Cxcr4, EDG2, RGS6, RGS2, and RGS4), or modulated during cardiac hypertrophy (Thbs4, Acta1, Fgg, and Fzd2) was validated by RT-PCR (Fig. 6) . Figure 6A shows the relative fold change of 13 genes found differentially expressed between the atria of VO vs. shamoperated animals. The RT-PCR validation of several differentially expressed genes found between the atria and ventricular tissues of VO animals are depicted in Fig. 6B . To validate the microarray data in an unbiased manner, two probe sets with unknown annotations (1373628_at and 1368987_at) and randomly selected genes (Prph1, Kcna5, and Epb4.1l3) were also validated by RT-PCR. The fold changes derived by RT-PCR were in agreement with the data obtained by the microarray experiment. Several genes exhibited a higher fold change ratio when analyzed by RT-PCR compared with microarray. Nevertheless, the changes were in the same direction.
Temporal mRNA expression of RASD1 was assessed in the atria and ventricles at 1, 2, 7, and 28 days postsham or post-VO shunt surgery (Fig. 7) . In the atria, RASD1 expression levels decreased significantly 2 days post-VO shunt surgery and stayed low throughout the time-course experiment, compared with sham-operated animals. No significant gene expression changes of RASD1 were observed in the ventricles.
RASD1 is a gene of particular interest since it is highly expressed in the atria compared with the ventricles and is uniquely downregulated in the atria during VO. Immunofluorescence analysis of the atrial-derived HL-1 cells, demonstrated that RASD1 was particularly abundant in the perinuclear region of atrial cardiocytes (Fig. 8) ; an area known to contain atrial specific granules (2, 29) . The perinuclear expression pattern of RASD1 in these HL-1 cells was similar to the pattern observed for G␣o (Fig. 9) .
RASD1 RNAi knockdown modulates ANF secretion in HL-1 cells.
To further investigate the role of RASD1, we performed RNAi knockdown experiments in HL-1 cells. Transfection efficiency was assessed by TYE 563-labeled transfection control (not shown). RASD1 was successfully knockdown with dicer-substrate 27-mer duplexes, denoted as siRASD1. HL-1 cells were either incubated with siRASD1 for up to 72 h, or with siRNA targeting ANF (siANF), or both siRASD1 and siANF. Gene-targeted knockdown efficiency was assessed by RT-PCR. On average RASD1 expression was decreased by 71%, and ANF by 87%, compared with the RNAi scrambled negative control. HL-1 cell basal secretion of ANF was significantly increased by siRASD1 at 48 and 72 h posttransfection (2.07-and 4.77-fold vs. scrambled negative control, respectively), while siANF completely abolished basal ANF secretion (Fig. 10A) . The amount of ANF measured in the media from the siANF group was not significantly different than the media collected from cell-free gelatin/fibronection-coated wells. The inhibition of ANF basal secretion by siRASD1 was also observed in the double knockdown of RASD1 and ANF (Fig. 10A) . Knockdown of RASD1 did not affect ANF expression levels (Fig. 10B) . Pharmacological stimulation of ANF secretion by the G i/o agonist Mastoparan-7 (MAS-7) increased ANF secretion in all RNAi conditions, demonstrating that RNAi mediated knockdown of RASD1 did not deplete ANF storage pool (Fig. 10C) .
RNAi knockdowns of heterotrimeric G proteins modulate ANF secretion in HL-1 cells.
Since RASD1 has been demonstrated to modulate heterotrimeric G␣ i/o ␤␥ protein signaling (4, 22, 31) RNAi knockdown of G␣ o (siG␣ o ), G␤ 1 (siG␤ 1 ), and G␥ 2 (siG␥ 2 ), in combination with siRASD1 was done in HL-1 cells. On average, the mRNA expression level of the heterotrimeric G-protein subunits G␣ o , G␤ 1 , and G␥ 2 were decreased by 82, 89, and 86%, respectively, compared with the RNAi scrambled negative control. Western blot analysis of RASD1 and G␣ o in RNAi-transfected HL-1 cells is shown in Fig. 11 , A and B. Endogenous protein expression levels in both atrial and ventricular tissues of pro-ANF, G␣ o , and RASD1 are shown in Fig. 11C .
Knockdown of G␣ o reduced ANF secretion levels by 1.58-fold (P ϭ 0.025), compared with negative control. The stimu- latory effect (3.7-fold) of siRASD1 on ANF secretion was blunted when HL-1 cells were cotransfected with siG␣o (Fig. 12A , compare siRASD1 vs. siRASD1 ϩ siG␣ o ). RNAi-targeted knockdown of G␤ 1 ␥ 2 subunits significantly reduced ANF secretion by 1.73-fold, compared with negative control (Fig. 12B) . Cotransfection of siRASD1 and siG␤ 1 ␥2 significantly reduced ANF secretion levels by 2.3-fold, compared with siRASD1. However, ANF secretion levels were still significantly higher (1.62-fold; P ϭ 0.002) than cells transfected with siG␤ 1 ␥ 2 .
DISCUSSION
The aorto-caval shunt procedure used in the present work is an in vivo experimental hemodynamic overload model that generates a volume or diastolic overload as a consequence of the diversion of a portion of arterial blood flow to the venous circulation. The needle puncture technique that induces VO has been previously shown to produce compensated cardiac hypertrophy between 2-8 wk postshunt surgery with rare occurrences (Ͻ3%) of overt heart failure before 8 wk (5, 6, 36) . The increased atrial distension associated with VO is also accompanied by an increased expression and secretion of the cardiac NPs (10), as shown in the present work. Hence the aorto-caval shunt is an ideal model for the analysis of the molecular changes involved in the stimulation of the endocrine heart. In the present work, several transcripts were found differentially expressed between the atria and ventricles based on innate tissue differences themselves or as a result of VO. In particular, a number of G-protein signaling transcripts as well as their accessory proteins were found differentially expressed between the atria and ventricles but a subset of them displayed an interaction effect, i.e., they were differentially expressed due to the experimental condition as well as their tissue of origin. This notably included RASD1, also known as dexamethasone-induced Ras-related protein 1 (Dexras1), which is highly expressed in the heart, with higher expression in the atria compared with the ventricles (24) . Under chronic hemodynamic overload, RASD1 was significantly downregulated in the both left and right atria but not in the ventricles. The temporal gene expression regulation of RASD1 was assessed in the atria and ventricles at 1, 2, 7, and 28 days postsham or post-VO shunt surgery. RASD1 expression levels decreased significantly 2 days post-VO shunt surgery and remained suppressed throughout the time-course experiment (Fig. 7) . This temporal regulation coincides with the increase in plasma secretion of ANF observed on days 2, 7, and 28 post-VO shunt surgery (refer to Fig. 2 ). These observations suggest an inverse correlation between RASD1 expression levels and ANF secretion. Indeed, knockdown of RASD1 in HL-1 cells significantly increased basal ANF secretion, mimicking what was observed in vivo and suggesting a negative modulator role for RASD1 on ANF secretion. Interestingly, double knockdown of RASD1 and ANF in HL-1 cells completely abolished the increased secretory response observed under RASD1 knockdown conditions. The extent of inhibition of ANF secretion in double knockdown was similar to that observed in ANF targeted knockdown alone. These results suggest that the increased ANF secretion observed following RASD1 knockdown does not derive from a pool of ANF already present (older) in the cell at the time of transfection with ANF RNAi. To validate this interpretation of the results, pharmacological stimulation of ANF secretion was carried out with MAS-7, a mastoparan derivative that activates G i/o proteins in a manner analogous to cognate agonists of G i/o -protein-coupled receptors. The rationale behind the use of MAS-7 derives from the fact that MAS-7 was previously shown to stimulate ANF secretion from isolated perfused beating atria, which pharmacologically mimics the mechanical activation of G i/o in stretch-secretion coupling. MAS-7 significantly stimulated ANF secretion under all RNAi knockdown conditions, including HL-1 cells transfected with RNAi targeting ANF, suggesting that MAS-7 stimulates release from ANF storage pools available even after inhibition of ANF synthesis by RNAi. RNAi knockdown of RASD1 did not alter the potency of MAS-7 on ANF secretion, demonstrating that the cellular ANF content was not depleted due to inhibition of RASD1 before MAS-7 stimulation. Hence, these results are consistent with the view that RASD1 preferentially modulate the secretion of newly synthesized ANF.
Modulation of heterotrimeric G i/o protein signaling pathway by RASD1 has been previously documented. In the absence of receptor stimulation, RASD1 specifically activates G i/o heterotrimeric signaling pathways by promoting nucleotide exchange on G␣ i/o proteins and enhancing G␤␥ uncoupling from G␣ i/o (7). The G␤␥-mediated activation of ERK1/2 pathway by RASD1 is sensitive to PTX treatment as well as ␤-adrenergic receptor kinase carboxyl terminus (scavenger of free G␤␥; Ref. 12). Furthermore, RASD1 expression has been shown to inhibit adenylyl cyclase activity and downstream signaling by cAMP-responsive nuclear transcription factor (13) . Hence, RASD1 acts on both G␣ i/o and G␤␥ through ligand receptorindependent activation of G i/o protein signaling. However, Graham et al. (12) demonstrated that RASD1 acts as an inhibitor of ligand-dependent ERK1/2 signaling cascade by the G i -coupled N-formyl peptide receptor. Similarly, Takesono et al. (31) , showed RASD1 inhibitor activity of G-proteincoupled inwardly rectifying potassium channels (Kcnj3,5) activated by the GPCR cholinergic receptor muscarinic 2 and suggested that RASD1 may antagonize GPCR signaling by modifying the pool of heterotrimeric G proteins available for receptor coupling.
RNAi-mediated knockdown of heterotrimeric G proteins was carried out in HL-1 cells to identify RASD1 effector proteins. Knockdown the G␣ o1 protein was undertaken since it was previously demonstrated that stretch-secretion coupling of ANF is mediated by heterotrimeric G␣ i/o proteins (2) and that G␣ o is highly abundant in atrial tissue (24) . Since RASD1 modulates both branches of the G-protein-signaling cascade, i.e., G␣ i/o and G␤␥ (8, 12, 13) , the G␤␥ subunits were also knocked down. Given that RASD1 has been shown, by yeasttwo-hybrid and coimmunoprecipitation studies, to interact with the G␤ 1 subunit (16, 32) and that G␤ 1 can interact with most G␥ subunits (18) , this subunit was selected for targeted knockdown. The rational employed in the choice of a G␥ subunit was based on the observation that G␥ 2 was significantly more abundant in the normal atria compared with the ventricles (24) . RNAi-targeted knockdown of the heterotrimeric G proteins ␣ o1 and ␤ 1 ␥ 2 significantly reduced ANF secretion, compared with the negative control, under basal conditions indicating that both branches of the G-protein-signaling cascade, i.e., G␣ o and G␤␥, influence ANF secretion. RNAi-mediated double knockdown of the G-protein subunits ␣ o1 or ␤ 1 ␥ 2 and RASD1 considerably reduced ANF secretion levels, compared with RASD1 targeted knockdown. The data obtained from these transfection studies indicate that RASD1 may negatively modulate the heterotrimeric G proteins and by consequence ANF secretion, since in the absence of these G proteins the stimulatory effect of RASD1 knockdown on ANF secretion is partially eliminated. The intermediate secretory effect observed under double knockdown conditions (RASD1 and G␣ o1 or G␤ 1 ␥ 2 ) suggests that RASD1 negatively modulates other effectors.
Regulation of hormone secretion is emerging as an important biological role of RASD1. Constitutively active RASD1 has been found to inhibit spontaneous and, to a greater extent, cAMP-stimulated secretion of human growth hormone in AtT-20 corticotroph cells (11) , indicating that RASD1 may act at the level of the dense core secretory granule pathway. RASD1 was also shown to attenuate agonist-dependent Ca v 2.2 channel inhibition through G i -coupled receptors in HEK293 cells, an effect that was blocked by PTX (33) . Hence, RASD1 appears to modulate ion influx and thereby potentially influencing Ca 2ϩ -dependent events such as hormone secretion. In the context of cardiac hormone secretion, the differential expression of RASD1 in the heart is of particular interest since stretch-secretion coupling of ANF and BNP secretion is mediated by PTX sensitive G␣ i/o (2) . The selective downregulation of RASD1 in the VO atria may be a process that ensures successful coupling of G␣ i/o proteins to GPCRs, since the interaction of RASD1 with the heterotrimeric G proteins would diminish their availability to the activated GPCR and thus partially blunt G i PCR-mediated signaling. Further, since RASD1 modulates both G␣ i/o and G␤␥ signaling (7, 12, 13) , it is possible that RASD1 tonically inhibits ANF secretion by modulating these heterotrimeric G proteins. Alternatively, RASD1 may have a role in sorting or trafficking secretory proteins into regulated granules and in its absence the secretory proteins are diverted to the constitutive pathway. This could explain why RASD1 expression levels are low in the ventricles compared with the atria, since ventricular cardiocytes are thought to secrete the natriuretic peptides ANF and BNP at a comparatively low rate and through a constitutive secretory pathway. The RASD1 role in targeting or sorting the secretory proteins to granules for long-term storage would not be necessary in ventricular cardiocytes, since under pathophysiological conditions, the ventricles continuously synthesis and immediately secrete the NPs, without any evidence of secretory granule storage (3, 19) .
Overall, the data developed in this investigation provide insight into the expression profiles of genes particularly centered in the secretory function of the heart under chronic VO. As expected, chronic VO produced a potent hypertrophic response and reexpression of the cardiac fetal gene program.
Differential regulation of signaling molecules was apparent, including mechanosensors and accessory proteins to G-protein signaling. The specific downregulation of RASD1 in the VO atria indicates a role for this accessory protein as a molecular link regulating ANF secretion. The increase in ANF secretion following RNAi targeted knockdown of RASD1 clearly supports a negative modulator role for RASD1 in ANF secretion. This molecular mechanism illustrates for the first time the concept of inhibitory protein regulators of ANF release. The novel function identified herein for RASD1 in the atria is of considerable biological importance with potential therapeutic implications for cardiovascular disease given the fact that the secretory impairment of the cardiac natriuretic hormones can negatively impact cardiovascular homeostasis, a fact evidenced by the genetic disruption of the natriuretic peptide system (17, 20, 23, 27) . Hence, RASD1 emerges as a unique therapeutic target that could be manipulated to enhance ANF secretion. Subsequent analysis of RASD1-interacting partners as well as a RASD1 knockout mouse will undoubtedly give additional insight into the role and importance of RASD1 in regulating ANF secretion. This appears a worthwhile pursuit given the importance of ANF and BNP in the maintenance of cardiovascular homeostasis and myocardial remodeling in both healthy and diseased hearts. 
